Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
May 10, 2018 12:32 PM EDT
Citi analyst Yigal Nochomovitz came out to defend Puma Biotechnology (NASDAQ: PBYI), saying the sell-off is overdone and to buy the dip.
He said the Possible explanations in order of likelihood 1) Lower apparent demand (NRx / new specialty pharmacy pt adds) in April (~230 / 280) vs. March (~300 / 342), 2)... More
May 10, 2018 6:28 AM EDT
BofA/Merrill Lynch lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $111.00 (from $115.00) while maintaining a Buy rating.
...
More
May 9, 2018 4:10 PM EDT
Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.65), $0.24 better than the analyst estimate of ($0.89).
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
...
More
